Type 1 diabetes incidence in children and adolescents during the COVID-19 pandemic in Germany. (November 2022)

• Record Type: Journal Article
• Authors: van den Boom, Louisa; Kostev, Karel; Kuss, Oliver; Rathmann, Wolfgang; Rosenbauer, Joachim
• Is Part Of: Diabetes research and clinical practice. Volume 193(2022)
• Publication Date: 2022-11
• Subjects: Type 1 diabetes -- Incidence -- Children and adolescents -- COVID-19 -- Insulin therapy; UK United Kingdom -- HCP healthcare professional -- LRx longitudinal prescription -- LOESS locally estimated scatterplot smoothing -- MIC minimal information criteria -- AR(I)MA autoregressive (integrated) moving average -- IRR incidence rate ratio -- SAS Statistical Analysis Software -- DPV Diabetes-Patienten-Verlaufsdokumentation -- ACE-2 angiotensin-converting enzyme-2 -- SARS-CoV 2 severe acute respiratory syndrome coronavirus type 2 -- COVID-19 coronavirus disease 2019 -- PY person-years -- CI confidence interval; Diabetes -- Periodicals; Diabetes Mellitus -- Periodicals; 616.462
• DOI: 10.1016/j.diabres.2022.110146
• Languages: English
• ISSNs: 0168-8227

Abstract

Abstract: Aims/hypothesis: The aim of this study was to analyze the incidence of type 1 diabetes in children and adolescents (<20 years of age) during the COVID-19 pandemic (3/2020 to 12/2021) in Germany. Methods: The present study was based on the IQVIA longitudinal prescription database (LRx), All persons (age ≤ 20 years) with new insulin prescriptions from 2016 to 2021 (index date) were selected and stratified by age group. Weekly (age-specific) data were used to forecast the prescription incidence for the pandemic period based on pre-pandemic data and to explore the relationship between weekly reported age-specific COVID-19 incidences and type 1 diabetes incidence and rate ratios of observed vs. predicted diabetes incidence respectively. Results: During the pre-pandemic period, there was a stable higher insulin prescription incidence during the winter period and a lower insulin prescription incidence during summer. During the pandemic period, there was less seasonal variation in incidence related to the finding that the observed incidence during summer in 2002 and 2021 was 44 % and 65 %, higher, respectively, than the expected incidence based on pre-pandemic year. We did not find any cross-correlations between the COVID-19 incidence and the type 1 diabetes incidence for any age group. Likewise, there were no cross-correlations between the COVID-19 incidence and the incidence rate ratios of observed incidences to predicted incidences. Conclusions/interpretation: During the COVID-19 pandemic, there was less seasonal variation in the incidence of type 1 diabetes (defined by new insulin prescriptions), with higher observed than expected incidences during summer. We found no evidence that the increase in type 1 diabetes incidence during the COVID-19 pandemic relates to direct effects of COVID-19 pandemic.